
Clinical-stage biotechnology company One-carbon Therapeutics has announced that the first subject has been dosed in its clinical trial for TH9619, …
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

